ERBB2 and neoplasm: Additionally, Intratumor heterogeneity of HER2 expression/amplification within a single tumor present in breast cancer might affect treatment responses to HER2-targeted therapy, including trastuzumab, as the fraction of HER2 non-amplified cells remains and acts as a driver of therapeutic resistance [87].